ArticleToxicology research2025
Sevoflurane alleviates hypoxia/reoxygenation-induced myocardial cell injury by regulating miR-93-5p.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to investigate the action of miR-93-5p in sevoflurane (Sev) preconditioning to protect against hypoxia/reoxygenation (H/R)-induced myocardial cell injury. H9c2 cells were preconditioned with Sev at concentrations of 1%, 2% and 4%, and subjected to H/R induction to establish the model. RT-qPCR was used to test miR-93-5p and NPAS2 levels. CCK8 assay and flow cytometry were used to detect cell viability and apoptosis. ELISA assays were used to measure myocardial injury markers (cTnI, CK-MB, MYO), as well as inflammatory factors (IL-6, IL-β, TNF-α). SOD and MDA kits were performed to detect oxidative stress levels. To investigate the impact of miR-93-5p on the protective effects of Sev pretreatment, we conducted transfection of miR-93-5p mimic. The connection of miR-93-5p with NPAS2 was confirmed using luciferase reporter gene assay. Our findings revealed that H/R treatment reduced cell viability, but Sev pretreatment enhanced it. In addition, Sev preconditioning reduced H/R-induced apoptosis, cTnI, CK-MB, MYO, MDA, IL-6, IL-β, and TNF-α levels, while elevated SOD levels. The miR-93-5p levels elevated with prolonged hypoxia time, but decreased with higher Sev pretreatment concentration. Transfection of miR-93-5p mimic attenuated protective efficacy by Sev preconditioning in myocardial cells. Besides, miR-93-5p targeted NPAS2 and negatively regulated it. In conclusion, our study demonstrated that sevoflurane preconditioning attenuated H/R-induced myocardial cells injury by modulating miR-93-5p.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.